BridgeBio口服Infigratinib新药申请获FDA受理并纳入优先审评,用于治疗儿童软骨发育不全

美股速递
Oct 06

BridgeBio Pharma公司宣布,其用于治疗儿童软骨发育不全的口服药物Infigratinib的新药申请已获得美国食品药品监督管理局(FDA)受理,并被授予优先审评资格。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10